Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sets New 52-Week High – Time to Buy?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) shares reached a new 52-week high on Tuesday . The stock traded as high as $14.55 and last traded at $14.11, with a volume of 1491914 shares. The stock had previously closed at $13.58.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on BAYRY. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Barclays upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 20th. Finally, Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Three research analysts have rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company’s stock. According to data from MarketBeat, Bayer Aktiengesellschaft currently has an average rating of “Buy”.

Bayer Aktiengesellschaft Stock Up 6.0%

The firm’s 50 day simple moving average is $11.95 and its 200 day simple moving average is $9.49. The company has a market cap of $56.59 billion, a price-to-earnings ratio of -159.98, a price-to-earnings-growth ratio of 4.88 and a beta of 0.67. The company has a quick ratio of 0.71, a current ratio of 1.14 and a debt-to-equity ratio of 1.10.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.